State of the art : approved and emerging JAK inhibitors for rheumatoid arthritis
INTRODUCTION: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In the past decade, many treatments have emerged to expand the therapeutic armamentarium of rheumatologists. Among emerging treatments, Janus Kinase inhibitors (JAKi) are promising in treating RA and several other inflammatory conditions, such as psoriatic arthritis (PsA). The JAK/STAT signaling pathway is located downstream certain cytokines receptors that are known to be involved in RA pathogenesis. So far, three JAKi are approved for the treatment of RA, while other JAKi, are under investigation.
AREAS COVERED: Herein, the authors review those JAKi approved and emerging for the treatment of RA and provide their expert perspectives on the subject area.
EXPERT OPINION: JAKi represent an interesting alternative to other DMARDs when MTX has failed. Long-term extension studies are still ongoing, but one can assume that most of the major safety concerns have already come out. Switching from one JAKi to another DMARD has been little studied, but in such cases, preferring a treatment which does not interfere with the JAK/STAT pathway seems to be a reasonable choice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert opinion on pharmacotherapy - 22(2021), 2 vom: 23. Feb., Seite 205-218 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Jammal, Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 23.02.2021 Date Revised 20.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14656566.2020.1822325 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315383631 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315383631 | ||
| 003 | DE-627 | ||
| 005 | 20231225154810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14656566.2020.1822325 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315383631 | ||
| 035 | |a (NLM)32967471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El Jammal, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a State of the art |b approved and emerging JAK inhibitors for rheumatoid arthritis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2021 | ||
| 500 | |a Date Revised 20.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In the past decade, many treatments have emerged to expand the therapeutic armamentarium of rheumatologists. Among emerging treatments, Janus Kinase inhibitors (JAKi) are promising in treating RA and several other inflammatory conditions, such as psoriatic arthritis (PsA). The JAK/STAT signaling pathway is located downstream certain cytokines receptors that are known to be involved in RA pathogenesis. So far, three JAKi are approved for the treatment of RA, while other JAKi, are under investigation | ||
| 520 | |a AREAS COVERED: Herein, the authors review those JAKi approved and emerging for the treatment of RA and provide their expert perspectives on the subject area | ||
| 520 | |a EXPERT OPINION: JAKi represent an interesting alternative to other DMARDs when MTX has failed. Long-term extension studies are still ongoing, but one can assume that most of the major safety concerns have already come out. Switching from one JAKi to another DMARD has been little studied, but in such cases, preferring a treatment which does not interfere with the JAK/STAT pathway seems to be a reasonable choice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a JAK inhibitor | |
| 650 | 4 | |a baricitinib | |
| 650 | 4 | |a filgotinib | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a tofacitinib | |
| 650 | 4 | |a upadacitinib | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Sève, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Gerfaud-Valentin, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Jamilloux, Yvan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d 1999 |g 22(2021), 2 vom: 23. Feb., Seite 205-218 |w (DE-627)NLM111602130 |x 1744-7666 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:2 |g day:23 |g month:02 |g pages:205-218 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14656566.2020.1822325 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 2 |b 23 |c 02 |h 205-218 | ||